CL2014001299A1 - Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor. - Google Patents

Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor.

Info

Publication number: CL2014001299A1
Authority: CL; Chile
Prior art keywords: conjugate; drug; growth factor; epidermal growth; treat tumor
Prior art date: 2011-11-16

Application number

CL2014001299A

Other languages

English (en)

Inventor

John Stephen Hill

Kevin J Hamblett

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-16

Filing date

2014-05-16

Publication date

2014-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-16 Application filed by Amgen Inc filed Critical Amgen Inc

2014-10-10 Publication of CL2014001299A1 publication Critical patent/CL2014001299A1/es

Links

102000009024 Epidermal Growth Factor Human genes 0.000 title 1
101800003838 Epidermal growth factor Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
229940125644 antibody drug Drugs 0.000 title 1
229940116977 epidermal growth factor Drugs 0.000 title 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Botany (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2014001299A 2011-11-16 2014-05-16 Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor. CL2014001299A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161560731P	2011-11-16	2011-11-16
US201261727029P	2012-11-15	2012-11-15

Publications (1)

Publication Number	Publication Date
CL2014001299A1 true CL2014001299A1 (es)	2014-10-10

Family

ID=47258124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001299A CL2014001299A1 (es)	2011-11-16	2014-05-16	Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor.

Country Status (21)

Country	Link
US (1)	US20140314667A1 (es)
EP (1)	EP2780040A1 (es)
JP (1)	JP2015500205A (es)
KR (1)	KR20140091064A (es)
CN (1)	CN104168922A (es)
AP (1)	AP2014007638A0 (es)
AU (1)	AU2012340174A1 (es)
BR (1)	BR112014011912A2 (es)
CA (1)	CA2855746A1 (es)
CL (1)	CL2014001299A1 (es)
CO (1)	CO6980620A2 (es)
CR (1)	CR20140267A (es)
EA (1)	EA201490974A1 (es)
HK (1)	HK1202252A1 (es)
IL (1)	IL232497A0 (es)
MX (1)	MX2014005957A (es)
PE (1)	PE20141937A1 (es)
PH (1)	PH12014501103A1 (es)
SG (1)	SG11201402365RA (es)
WO (1)	WO2013075048A1 (es)
ZA (1)	ZA201403541B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2457586A1 (en)	2003-06-27	2012-05-30	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
ES2996807T3 (en)	2013-03-15	2025-02-13	Regeneron Pharma	Biologically active molecules, conjugates thereof, and therapeutic uses
CN105377897A (zh)	2013-05-03	2016-03-02	俄亥俄州创新基金会	Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN105473616B (zh) *	2013-07-05	2020-08-04	形成生物产品有限公司	Egfr抗体缀合物
NZ724229A (en) *	2014-03-11	2023-06-30	Regeneron Pharma	Anti-egfrviii antibodies and uses thereof
ES2871598T3 (es) *	2014-11-25	2021-10-29	Pharmabcine Inc	Anticuerpo novedoso contra EGFRvIII y composición que comprende el mismo
EP3258967A4 (en) *	2015-02-20	2018-10-03	Ohio State Innovation Foundation	Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016146143A1 (en) *	2015-03-16	2016-09-22	Amal Therapeutics Sa	Cell penetrating peptides and complexes comprising the same
WO2016164370A1 (en)	2015-04-06	2016-10-13	Ohio State Innovation Foundation	Egfr-directed car therapy for glioblastoma
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TW201936640A (zh) *	2016-01-21	2019-09-16	美商輝瑞股份有限公司	對表皮生長因子受體變異體ｉｉｉ具特異性之抗體類及彼等之用途
CN114716557A (zh)	2016-02-03	2022-07-08	安进研发（慕尼黑）股份有限公司	Psma和cd3双特异性t细胞接合抗体构建体
KR101887977B1 (ko)	2016-02-15	2018-08-14	사회복지법인 삼성생명공익재단	EGFRvIII (Epidermal Growth Factor Receptor Variant III)에 대한 항체 및 이의 용도
WO2017142294A1 (ko) *	2016-02-15	2017-08-24	사회복지법인 삼성생명공익재단	EGFRvIII에 대한 항체 및 이의 용도
RS65430B1 (sr)	2016-03-16	2024-05-31	Amal Therapeutics Sa	Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
EP3515476B1 (en)	2016-09-21	2024-05-22	Amal Therapeutics SA	Fusion comprising a cell penetrating peptide, a multiepitope and a tlr peptide agonist for treatment of cancer
WO2019114804A1 (zh) *	2017-12-13	2019-06-20	凯惠科技发展(上海)有限公司	一种EGFRvIII抗体及其偶联物、制备方法和应用
MX2021011320A (es)	2019-03-19	2021-12-10	Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron	Terapia de combinacion con omomyc y un anticuerpo que se une a pd-1 o a ctla-4 para el tratamiento del cancer.
CN113082216B (zh) *	2021-04-25	2022-07-01	吉林大学	含miR-124的胶质瘤细胞外泌体及其制备方法和应用
JP2024539550A (ja) *	2021-09-29	2024-10-29	ナショナルリサーチカウンシルオブカナダ	ヒト化抗ｅｇｆｒｖｉｉｉ抗体及びその抗原結合断片
JP2025532635A (ja) *	2022-09-19	2025-10-01	ソノマバイオセラピューティクス，インコーポレイテッド	制御性ｔ細胞を標的化して化膿性汗腺炎を治療するためのシトルリン化抗原特異的キメラ抗原受容体
IL320482A (en)	2022-10-25	2025-06-01	Peptomyc S L	Combination therapy for cancer treatment
AU2024285758A1 (en)	2023-06-07	2025-12-18	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with braf inhibitors for the treatment of cancer
EP4473974A1 (en)	2023-06-07	2024-12-11	Peptomyc, S.L.	Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251846A1 (en)	2023-06-07	2024-12-12	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with mek inhibitors for the treatment of cancer

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3180193A (en)	1963-02-25	1965-04-27	Benedict David	Machines for cutting lengths of strip material
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164686A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE12348T1 (de)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4414205A (en)	1981-08-28	1983-11-08	University Patents, Inc.	Cell growth inhibitory substances
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
JPS58166633A (ja)	1982-03-29	1983-10-01	Toshiba Corp	有機溶媒電池用正極
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4486414A (en)	1983-03-21	1984-12-04	Arizona Board Of Reagents	Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de)	1983-09-26	1991-01-16	Udo Dr. Ehrenfeld	Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
JPS62170639A (ja)	1986-01-22	1987-07-27	株式会社システムメンテナンス	防蟻板の取付け工法
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US4816444A (en)	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
US5476996A (en)	1988-06-14	1995-12-19	Lidak Pharmaceuticals	Human immune system in non-human animal
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5076973A (en)	1988-10-24	1991-12-31	Arizona Board Of Regents	Synthesis of dolastatin 3
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US4978744A (en)	1989-01-27	1990-12-18	Arizona Board Of Regents	Synthesis of dolastatin 10
US4879278A (en)	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en)	1989-05-18	1991-01-22	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
ES2125854T3 (es)	1989-08-09	1999-03-16	Rhomed Inc	Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
WO1991003489A1 (en)	1989-09-08	1991-03-21	The Johns Hopkins University	Structural alterations of the egf receptor gene in human gliomas
US5981725A (en)	1989-09-08	1999-11-09	The Johns Hopkins Univiersity	Structural alterations of the EGF receptor gene in human tumors
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en)	1989-11-13	1992-08-11	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr)	1990-06-29	1992-01-03	Thomson Csf	Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
WO1992022670A1 (en)	1991-06-12	1992-12-23	Genpharm International, Inc.	Early detection of transgenic embryos
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
EP0648265A4 (en)	1992-06-18	1996-12-04	Genpharm Int	PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
JPH07509137A (ja)	1992-07-24	1995-10-12	セル　ジェネシス，インク．	異種抗体の生産
US5372783A (en)	1992-08-03	1994-12-13	Sapidyne, Inc.	Assay system
US5958708A (en)	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en)	1993-01-07	1999-11-09	Genpharm Internation, Inc.	Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (en)	1993-04-26	2010-12-21	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5811524A (en)	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
KR100308764B1 (ko)	1995-08-29	2001-12-17	마나배게이사꾸	키메라동물및그의제작법
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
CA2322749A1 (en)	1998-03-03	1999-09-10	Abgenix, Inc.	Cd147 binding molecules as therapeutics
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2003523771A (ja)	2000-02-25	2003-08-12	ザガバメントオブザユナイテッドステイツ，アズレプレゼンテッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	改善された細胞傷害性および収率を有する抗ＥＧＦＲｖＩＩＩｓｃＦｖ、それに基づく免疫毒素、ならびにその使用方法
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1461442B1 (en)	2001-11-30	2017-09-06	Amgen Fremont Inc.	Transgenic animals bearing human ig lambda light chain genes
EP1554576B9 (en)	2001-12-03	2008-08-20	Amgen Fremont Inc.	Identification of high affinity molecules by limited dilution screening
DE60226641D1 (de)	2001-12-03	2008-06-26	Amgen Fremont Inc	Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US7820166B2 (en)	2002-10-11	2010-10-26	Micromet Ag	Potent T cell modulating molecules
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1930187B (zh) *	2003-06-27	2015-08-19	艾默根佛蒙特有限公司	针对表皮生长因子受体的缺失突变体的抗体及其使用
EP2457586A1 (en) *	2003-06-27	2012-05-30	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7064994B1 (en)	2004-01-30	2006-06-20	Sun Microsystems, Inc.	Dynamic memory throttling for power and thermal limitations
RU2006132669A (ru)	2004-02-16	2008-03-27	Микромет Аг (De)	Связывающие молекулы, обладающие пониженной иммуногенностью
WO2006034035A2 (en)	2004-09-16	2006-03-30	Virogenomics, Inc.	Treatment of ischemia
AU2006301492B2 (en)	2005-10-11	2011-06-09	Amgen Research (Munich) Gmbh	Compositions comprising cross-species-specific antibodies and uses thereof
JP6071725B2 (ja)	2013-04-23	2017-02-01	カルソニックカンセイ株式会社	電気自動車の駆動力制御装置
US11284893B2 (en)	2019-04-02	2022-03-29	Covidien Lp	Stapling device with articulating tool assembly

2012
- 2012-11-16 HK HK15102782.1A patent/HK1202252A1/xx unknown
- 2012-11-16 CN CN201280067232.8A patent/CN104168922A/zh active Pending
- 2012-11-16 JP JP2014542531A patent/JP2015500205A/ja not_active Withdrawn
- 2012-11-16 SG SG11201402365RA patent/SG11201402365RA/en unknown
- 2012-11-16 KR KR1020147016092A patent/KR20140091064A/ko not_active Withdrawn
- 2012-11-16 EA EA201490974A patent/EA201490974A1/ru unknown
- 2012-11-16 US US14/358,641 patent/US20140314667A1/en not_active Abandoned
- 2012-11-16 BR BR112014011912A patent/BR112014011912A2/pt not_active IP Right Cessation
- 2012-11-16 AP AP2014007638A patent/AP2014007638A0/xx unknown
- 2012-11-16 AU AU2012340174A patent/AU2012340174A1/en not_active Abandoned
- 2012-11-16 WO PCT/US2012/065707 patent/WO2013075048A1/en not_active Ceased
- 2012-11-16 MX MX2014005957A patent/MX2014005957A/es not_active Application Discontinuation
- 2012-11-16 PE PE2014000701A patent/PE20141937A1/es not_active Application Discontinuation
- 2012-11-16 CA CA2855746A patent/CA2855746A1/en not_active Abandoned
- 2012-11-16 EP EP12791937.1A patent/EP2780040A1/en not_active Withdrawn
2014
- 2014-05-07 IL IL232497A patent/IL232497A0/en unknown
- 2014-05-15 ZA ZA2014/03541A patent/ZA201403541B/en unknown
- 2014-05-16 CL CL2014001299A patent/CL2014001299A1/es unknown
- 2014-05-16 PH PH12014501103A patent/PH12014501103A1/en unknown
- 2014-06-09 CR CR20140267A patent/CR20140267A/es unknown
- 2014-06-12 CO CO14127687A patent/CO6980620A2/es unknown

Also Published As

Publication number	Publication date
CO6980620A2 (es)	2014-06-27
MX2014005957A (es)	2015-02-04
EA201490974A1 (ru)	2014-09-30
PH12014501103A1 (en)	2014-10-20
IL232497A0 (en)	2014-06-30
ZA201403541B (en)	2015-12-23
CN104168922A (zh)	2014-11-26
SG11201402365RA (en)	2014-06-27
CA2855746A1 (en)	2013-05-23
JP2015500205A (ja)	2015-01-05
KR20140091064A (ko)	2014-07-18
PE20141937A1 (es)	2014-12-18
BR112014011912A2 (pt)	2017-05-16
AP2014007638A0 (en)	2014-05-31
CR20140267A (es)	2014-08-27
WO2013075048A1 (en)	2013-05-23
HK1202252A1 (en)	2015-09-25
AU2012340174A1 (en)	2014-05-29
US20140314667A1 (en)	2014-10-23
EP2780040A1 (en)	2014-09-24

Publication	Publication Date	Title
CL2014001299A1 (es)	2014-10-10	Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor.
CO6900118A2 (es)	2014-03-20	Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CO6831975A2 (es)	2014-01-10	Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
CO6930363A2 (es)	2014-04-28	Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PL2768493T3 (pl)	2020-03-31	Fitokannabinoidy do stosowania w leczeniu raka piersi
BR112014007603A2 (pt)	2017-06-13	métodos de tratamento do câncer
BR112013013781A2 (pt)	2016-09-13	anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
CL2012003385A1 (es)	2013-04-05	Tratamiento para la incontinencia.
PT2683384E (pt)	2016-03-11	Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
LT3333161T (lt)	2020-05-11	2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
BR112014012880A2 (pt)	2017-06-13	tratamento imunogênico do câncer
DK2681227T3 (da)	2016-02-22	Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
IL223201A (en)	2015-05-31	Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
HUE036872T2 (hu)	2018-08-28	Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
LT2707030T (lt)	2020-07-10	Vėžio gydymas
PL2739153T3 (pl)	2019-04-30	Leczenie raka sutka
BR112014028424A2 (pt)	2018-04-24	compostos de pirimidina para o tratamento de câncer
BR112014006482A2 (pt)	2017-05-16	uso de derivados de isossorbida para produção de preparações cosméticas
HRP20190046T1 (hr)	2019-05-03	Kombinirana terapija za liječenje raka
BR112013032876A2 (pt)	2017-01-24	uso de formulações, e, método para fertilizar plantas
BR112015006512A2 (pt)	2017-08-08	composição para tratar tecidos biológicos danificados
BR112014002830A2 (pt)	2017-06-13	fotossensibilizador para uso terapêutico
BR112013011659A2 (pt)	2016-08-02	métodos de tratamento do câncer
PL2729008T3 (pl)	2017-10-31	Systemy, sposoby i formulacje do leczenia raka
BR112012030927A2 (pt)	2017-12-05	fosfaplatinas e seu uso para o tratamento de cânceres